3rd Viral Vector Process Development & Manufacturing Summit
In 2025, viral vector-based biotechs achieved significant milestones, including BLA approvals from Adaptimmune (TECELRA), bluebird bio (LYFGENIA) and Pfizer (BEQVEZ), as well as Genezen’s $18.5M investment in viral vector manufacturing. With 800+ candidates in clinical trials and evolving FDA quality frameworks, the need to improve manufacturability and reduce COGs was urgent.
Returning to Boston, this summit focused on advancing AAV, AV, and LV processes, from upstream to downstream. Attendees explored cutting-edge technologies, case studies, and innovations in process development to drive scalable, high-quality viral vectors for the future of cell and gene therapeutics.
What You Missed:
Attendees explored practical strategies for maintaining product consistency and safety in large-scale viral vector operations, crucial for regulatory compliance and therapeutic effectiveness, with insights from Sangamo Therapeutics and Kite, A Gilead Company.
Attendees learned from Ultragenyx and Spirovant Sciences about creating standardized manufacturing processes that improve reproducibility and quality control, vital for ensuring therapeutic equivalence across production batches
Attendees explored advanced process optimization techniques for boosting viral yields while maintaining quality, emphasizing the reduction of defective particles that may impact therapeutic results, with insights from St. Jude’s Hospital, Apertura, and UCB
Attendees discussed cutting-edge purification methods from Sanofi that go beyond traditional ultracentrifugation, achieving high-purity viral vectors crucial for effective cell and gene therapies
Who Did Attendees Meet in 2025?
They connected with fellow Executive Directors, Vice Presidents, and Principal Scientists specializing in viral vector process development and manufacturing, alongside experts in Analytical Development, Regulatory Affairs, and CMC.
Attendees explored the latest advancements within the viral vector process development and manufacturing realm. The 3-days featured an in-depth regulatory considerations alignment workshop and technical case studies to transform development cost dynamics.
What Your Peers Had to Say
“I’m looking forward to learning about the latest advances in process development and manufacturing. Anything we as an industry can do to streamline vector production and reduce costs means we have a better chance at getting new therapies to patients who desperately need them.”
April Sena, Vice President, Technical Operations, Life Edit Therapeutics, 2025 Speaker